[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colonization-asymptomatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colonization-asymptomatic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,80,101,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100601137","phase-1-safety-and-efficacy-of-lyophilized-fecal-microbiota-transplantation-via-capsules-for-intestinal-multidrug-resistant-bacteria-decolonization-100601137",false,"NCT07106580","Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Via Capsules for Intestinal Multidrug-resistant Bacteria Decolonization","A Monocentric, Prospective, Randomized, Placebo-controlled, Double-blinded Trial Investigating the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Capsules in Decolonization of Patients With Intestinal Carriage of Multidrug-resistant Organisms","FORCE","Inclusion Criteria:\n\n* ≥ 18 years,\n* stool sample or rectal swab positive for MDRO (CRE, ESBL-E, VRE) within a week of randomization,\n* capable of swallowing oral capsules,\n* willing to give informed consent\n\nExclusion Criteria:\n\n* antibiotic treatment on the day of inclusion,\n* pregnant or breastfeeding, women of childbearing potential who are unwilling or unable to use an acceptable method of birth control,\n* patients with terminal diseases with expected life expectancy \\\u003C 6 months,\n* unwillingness to ingest the capsules,\n* a history of colectomy, present colostomy or ileostomy,\n* patients with the diagnosis\u002Ftreatment of inflammatory or functional bowel disease,\n* patients with malignant bowel diseases,\n* absolute neutrophil count \\\u003C 500\u002Fmm3,\n* selective digestive decolonization with antibiotics within 6 months before randomization,\n* severe allergy to capsule components","ALL","18 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of this clinical trial is to learn if oral capsules containing lyophilized stool from healthy donors (fecal microbiota transplantation or FMT) can safely and effectively decolonize multidrug-resistant organisms (MDROs) from the intestines in adults. The main questions it aims to answer are:\n\n1. Does FMT via oral capsules reduce or eliminate intestinal MDRO colonization?\n2. What side effects or adverse events occur after taking FMT capsules?\n\nResearchers will compare FMT capsules to placebo capsules to see if FMT is effective and safe for decolonizing MDROs.\n\nParticipants will:\n\n* Take either FMT capsules or placebo capsules by mouth\n* Attend 4 follow-up study visits over 6 months (180 days) for microbiological testing and safety monitoring\n* Provide stool samples and report any side effects",[28],"Colonization, Asymptomatic",[30,31,32,33,34,35],"FMT","Fecal microbiota transplantation","Colonization","MDRO","Multidrug-resistant bacteria","Lyophilization","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":40},"2025-07-28",{"date":44,"type":21},"2027-09",{"name":46,"class":47},"University of Rijeka","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100626772","phase-1-encapsulated-probiotics--gut-microbiota-100626772","NCT07439978","Encapsulated Probiotics & Gut Microbiota","A Physiological Study of a Fermented Yogurt Drink Containing Probiotics","Probiotics","Inclusion Criteria:\n\n* Capacity to obtain and sign informed consent before any study-related procedure\n* BMI range 18.5-31.9 kg\u002Fm2\n* Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages).\n* Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria will be excluded:\n\n* Smoking\n* Substance abuse\n* Pregnancy\n* Diagnosis of type 1 and\u002For type 2 diabetes\n* Current (or within the last 4 weeks prior to study start) use of probiotic supplementation.\n* Immobile (defined as the inability to participate in all study-related procedures)\n* History of complicated gastrointestinal surgery\n* Diagnosed with inflammatory bowel disease (IBD)\n* Current diagnosis of psychiatric disease\u002Fs or syndromes\n* Current diagnosis of neurodegenerative disease\n* Systemic use of antibiotics and\u002For steroid medication in the last 4 months prior to inclusion\n* Use of any non-steroidal anti-inflammatory drug (NSAID) more than 3 times a week for the last 2 months\n* Consumption of any NSAID within 7 days of study start\n* Any condition which could substantially interfere with intestinal barrier function (e.g. gluten sensitivity, lactose intolerance, celiac disease, IBS, IBD) or in any other way with the outcome of the study, as decided by the principal investigator's discretion\n* Regular smoking, use of snuff, nicotine, cannabidiol narcotics\u002Fsupplements, or e-cigarette use\n* Drinking more than 9 standard cups of alcohol per week and\u002For more than 3 standard cups of alcohol per occasion\n* Regular use, for more than three times a week for the last 2 months and\u002For 7 days prior to inclusion, of medications which, according to the principal investigator, can have an anti-inflammatory effect or affect in any way the intestinal barrier function or have an impact on the study analysis (such as laxatives, anti-diarrheal, anti-cholinergic, etc.)\n* After being included in the study, starting any medication or treatment that could potentially influence the study participation and\u002For study analysis.",true,"25 Years","65 Years",{"count":61,"type":21},50,[24],"The aim of this study is to determine whether encapsulation of probiotic bacteria using natural plant protein can enhance bacterial colonisation. Lactobacillus rhamnosus is an ideal strain for the intervention, as it has been shown to affect overall gut health, gut-brain axis, and brain function.\n\nTwenty-five participants aged 25 to 65 years will be recruited and assessed on four occasions to compare the blood and faecal effects of a 28-day ingestion of a yoghurt beverage with and without the probiotic strain of interest. The study window will be 70+\u002F13 days.\n\nThe current study will provide important information on the physiological function of probiotics in the small bowel. Understanding the underlying physiological effects of targeted probiotic delivery to the intestine and the impact on the microbiome is important for health outcomes.",[28,65],"Colonisation",[67,68,32,69],"Probiotic","Microbiota","Dairy","NOT_YET_RECRUITING","2026-05-05",{"date":73,"type":40},"2026-05-08",{"date":75,"type":21},"2026-04",{"date":77,"type":21},"2026-08",{"name":79,"class":47},"University College Dublin",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":67,"eligibilityCriteria":86,"healthyVolunteers":57,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100632176","phase-1-probiotic-delivered-to-the-small-intestine-changes-microbiota-100632176","NCT07510282","Probiotic Delivered to the Small Intestine Changes Microbiota","A Physiological Study on How Probiotic Delivered to the Small Intestine Changes Microbiota","Inclusion Criteria:\n\n* Capacity to obtain and sign informed consent before any study-related procedure\n* BMI range 18.5-31.9 kg\u002Fm2\n* Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages).\n* Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study.\n\nExclusion Criteria:\n\n* Smoking\n* Substance abuse\n* Pregnancy\n* Diagnosis of type 1 and\u002For type 2 diabetes\n* Current (or within the last 4 weeks prior to the study start) use of probiotic supplementation.\n* Immobile (defined as the inability to participate in all study-related procedures)\n* History of complicated gastrointestinal surgery\n* Diagnosed with inflammatory bowel disease (IBD)\n* Current diagnosis of psychiatric disease\u002Fs or syndromes\n* Current diagnosis of neurodegenerative disease\n* Systemic use of antibiotics and\u002For steroid medication in the last 4 months prior to inclusion\n* Use of any non-steroidal anti-inflammatory drug (NSAID) more than 3 times a week for the last 2 months\n* Consumption of any NSAID within 7 days of study start\n* Any condition which could substantially interfere with intestinal barrier function (e.g. gluten sensitivity, lactose intolerance, celiac disease, IBS, IBD) or in any other way with the outcome of the study, as decided by the principal investigator's discretion\n* Regular smoking, use of snuff, nicotine, cannabidiol narcotics\u002Fsupplements, or e-cigarette use\n* Drinking more than 9 standard cups of alcohol per week and\u002For more than 3 standard cups of alcohol per occasion\n* Regular use, for more than three times a week for the last 2 months and\u002For 7 days prior to inclusion, of medications which, according to the principal investigator, can have an anti-inflammatory effect or affect in any way the intestinal barrier function or have an impact on the study analysis (such as laxatives, anti-diarrheal, anti-cholinergic, etc.)\n* After being included in the study, starting any medication or treatment that could potentially influence the study participation and\u002For study analysis.",{"count":88,"type":21},25,[24],"This study will determine whether encapsulation of probiotic bacteria using natural plant protein can enhance bacterial colonisation. Lactobacillus rhamnosus is an ideal strain for the intervention, as it has been shown to affect overall gut health, gut-brain axis, and brain function. Participants aged 25 to 65 years will be recruited and assessed on four occasions to compare the effects of the blood chemicals and bacterial composition in faeces of a 28-day ingestion of a yoghurt beverage with and without the probiotic strain of interest. The study window will be 70+\u002F13 days. This study will provide important information regarding the physiological function of probiotics in the small intestine. Understanding the underlying physiological effects of targeted probiotic delivery to the intestine and the impact on the microbiome is important for health outcomes.",[28,32],[67,68,32,69],"2026-03-29",{"date":95,"type":40},"2026-04-03",{"date":97,"type":21},"2026-04-15",{"date":99,"type":21},"2026-12",{"name":79,"class":47},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100537798","phase-4-nasal-antisepsis-for-c-auris-prevention-100537798","NCT06282510","Nasal Antisepsis for C. Auris Prevention","Impact of Nasal Antisepsis on Candida Auris Colonization","Inclusion Criteria:\n\n* History of C. auris colonization or infection\n* Patient in a participating facility\n\nExclusion Criteria:\n\n* History of severe allergy to iodine-based products, defined as anaphylaxis or rash\n* Currently breastfeeding or pregnant\n* Non-English language speaking",{"count":109,"type":21},120,[111],"PHASE4","This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.",[114,28],"Candida Auris Infection",[116,117,32,118,119,120],"Candida auris","Decolonization","Infection Prevention","Povidone Iodine","Long-term Care","2025-10-13",{"date":123,"type":40},"2025-10-15",{"date":125,"type":40},"2024-01-29",{"date":127,"type":21},"2028-12",{"name":129,"class":47},"Mary K Hayden",3,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":48},"100564777","phase-4-decolonization-efficacy-of-polyhexanide-vs-mupirocin-100564777","NCT06633588","Decolonization Efficacy of Polyhexanide vs. Mupirocin","Surgical Prophylaxis: Assessing Decolonization Efficacy of Polyhexanide Versus Mupirocin and Chlorhexidine in Decolonizing Staphylococcus Aureus Preoperatively in Elective Spine Surgery (SPADE): A Pilot Randomized Controlled Trial","SPADE","Inclusion Criteria:\n\n* Age over 18 years\n* Scheduled for elective spinal surgery\n* Colonized with Staphylococcus aureus\n* Informed consent provided\n\nExclusion Criteria:\n\n* Emergency spine surgery\n* Methicillin-resistant Staphylococcus aureus (MRSA) or mupirocin-resistant S. aureus\n* Known allergies to products used in the trial\n* Pregnant or breastfeeding women\n* Recent antibiotic therapy (within 14 days)\n* Known non-compliance, substance abuse, or psychological disorders\n* Participation in another antimicrobial trial within the last 30 days",{"count":140,"type":21},24,[111],"This pilot randomized controlled trial evaluates the feasibility, tolerability, and preliminary efficacy of a decolonization regimen using polyhexanide in reducing Staphylococcus aureus colonization in the preoperative phase of elective spine surgery, compared to the standard mupirocin and chlorhexidine regimen. The trial involves 24 participants randomized into two groups: one receiving polyhexanide and the other receiving mupirocin and chlorhexidine. The primary outcome is the randomization rate, with secondary outcomes including other feasibility outcomes, tolerability, and efficacy measures such as the reduction in S. aureus colony-forming units (CFUs) and changes in the nasal and skin microbiome composition.",[144,28],"Staphylococcus Aureus",[146,147,148],"Staphylococcus aureus colonization","Spinal surgery","decolonization","2025-05-21",{"date":151,"type":40},"2025-05-28",{"date":153,"type":40},"2025-05-01",{"date":155,"type":21},"2027-04-30",{"name":157,"class":158},"Swiss Paraplegic Research, Nottwil","NETWORK"]